Amolyt Pharma

Amolyt Pharma specializes in peptides for the treatment of rare endocrine and metabolic disorders.

Health and bio Consumer and social

Latest funding

$140M Series B+ · January 6, 2023

Led by Intermediate Capital Group · Source: startupintros.com

Total raised: $294M across 3 sourced rounds

All 3 rounds ↓

Website: amolytpharma.com.

LinkedIn: linkedin.com.

Categories: Health and bio Consumer and social.

Sectors: Biotechnology, Health Care, Medical, Pharmaceutical, Wellness.

Stage: Series B+.

Based in: Écully, France.

Founded: 2015.

Total raised: $294M in 3 sourced rounds.

Last round: Jan 6, 2023 · 1,406 days ago.

Headcount: 11–50 employees.

On Recent Funding since: Nov 8, 2026.

Signals

Website registeredApr 20, 2020 (6 years old)

TIMELINE · MONEY RAISED

Amolyt Pharma | 2691 days on the record

Raised $294M in 3 sourced rounds

Money raised, round by round (amounts linked to their source). Pins are dated signals; hover the icons for dates.

Funding rounds

January 6, 2023
Series B+ · $140M
IIntermediate Capital Group (lead), SSofinnova Partners (lead), KKurma Partners, MMass General Brigham Ventures, NNovo Ventures, OOrbiMed, PPontifax, SSectoral Asset Management, TTekla Capital Management, TTurenne Capital
Source: startupintros.com
September 1, 2021
Series B+ · $80M
SSectoral Asset Management (lead), CCredit Agricole Entreprises, EEQT Life Sciences, EEurazeo, KKurma Partners, MMass General Brigham Ventures, NNovo Ventures, OOrbiMed, PPontifax, SSham
Source: startupintros.com
April 20, 2020
Website created
July 1, 2019
Series A · $74M
Source: startupintros.com

Founders and team

TA
Thierry Abribat Founder

LinkedIn
LJ
Louis J. Arcudi Chief Financial Officer
MS
Mark Sumeray Chief Medical Officer
MC
Michael Culler Chief Scientific Officer

Investors

Companies like Amolyt Pharma

NNoema PharmaSeries B+ · Nov 2025
GGutCRINESeed · Jun 2023
AAzafaros$150M Series B+ · May 2025
HHotSpot Therapeutics$100M Series B+ · Nov 2021
SSironaxSeries B+ · Sep 2025
RResalis Therapeutics$10.92M Series A · Jan 2024

Other companies backed by Intermediate Capital Group

DDraig Therapeutics$65M Series B+ · Jul 2026
MMediar Therapeutics$76M Series B+ · Jan 2026
FF2G$100M Series B+ · Sep 2024
GGrey Wolf Therapeutics$50M Series B+ · May 2024

Intermediate Capital Group portfolio →

Sources and API

Every amount links to the page it came from. * Estimated from an accelerator's published standard deal, not a company-specific disclosure. How Recent Funding sources and verifies funding data. The same data as JSON: /api/v1/companies/amolyt-pharma (get a free API key).